Accelerate target discovery and minimize translational risk with our specialized organoid sequencing services. Engineered to overcome the micro-biomass challenge, our end-to-end multi-omics platform offers ultra-low input DNA sequencing, high-fidelity RNA transcriptomics, and gentle single-cell analysis to definitively validate your tissue-derived 3D models.
Service Highlights:
Micro-Input Optimized: Specialized extraction protocols for delicate, low-yield 3D models.
End-to-End Solutions: Seamless workflow from nucleic acid extraction to integrated bioinformatics provided directly by our experts.
Model Fidelity Validation: Deep tumor-normal concordance analysis to guarantee preclinical relevance.
The Core Challenge: Securing Quality Data from Delicate 3D Models
Generating complex 3D tissue models is a time-intensive investment. However, securing high-quality sequencing data from these models presents a significant physical challenge. Standard bulk-tissue extraction protocols are simply too harsh for delicate, micro-input organoids. Applying generic extraction methods frequently leads to severe nucleic acid degradation, massive cellular death during dissociation, and ultimately, failed library preparations.
Furthermore, models derived from fine-needle aspiration (FNA) or slow-growing primary tissues often do not yield enough biomass to meet the standard input requirements of traditional sequencing providers. This forces researchers to over-culture their models, which introduces the severe risk of genetic drift and the loss of the original tumor phenotype.
We understand the frustration of losing precious samples. Our multi-omics platform is fundamentally built around specialized micro-input handling and gentle dissociation techniques. We utilize proprietary lysis reagents and temperature-controlled workflows designed explicitly to protect structural integrity and maximize yield from minimal biomass. By preventing sample loss at the physical processing stage, we ensure your downstream sequencing data is an unbiased, highly accurate reflection of your model's true biology.
Managing multiple disjointed teams for extraction, library prep, and sequencing creates fragmented data and introduces severe batch effects. We provide a consolidated, end-to-end workflow within our own facility, featuring transparent quality control (QC) checkpoints. These "stop-loss" gates ensure we only sequence viable, high-quality materials, protecting your research budget.
Sample Receipt & Logging: Immediate assessment of temperature stability and buffer integrity upon arrival.
Specialized Processing & QC: Gentle cell dissociation for single-cell projects, or micro-input nucleic acid extraction for bulk sequencing. QC Checkpoint: Rigorous evaluation of Cell Viability (>80% required) or RNA Integrity Number (RIN).
Library Construction: Low-input amplification and targeted enrichment utilizing industry-leading chemistry. QC Checkpoint: Fluorometric quantification of library fragment size and molarity.
High-Throughput Sequencing: Deep, uniform sequence generation across established high-throughput platforms. QC Checkpoint: Algorithmic assessment of Q30 quality scores and adapter contamination rates.
Integrated Bioinformatics: Raw data is processed through our custom pipelines, delivering interactive, publication-ready multi-omics reports tailored to your endpoints.
Profiling Strategy
Choosing Your Profiling Strategy: The Multi-Omics Matrix
Understanding which sequencing technology to deploy is critical for your project's success and budget. DNA sequencing tells you what mutations exist, bulk RNA sequencing shows overall pathway activity, and single-cell RNA sequencing reveals how individual cells behave within the 3D ecosystem. Use our selection matrix below to identify the optimal strategy for your specific research endpoints.
Cellular heterogeneity and rare subpopulation identification
Isolating specific drug-resistant subclones and mapping complex microenvironments
Solution Selection Strategy:
Choose WES when your primary goal is to establish the baseline genetic fidelity. This confirms that your cultured model has not undergone severe genetic drift and still carries the critical structural variations present in the primary tissue.
Opt for Bulk mRNA for rapid, cost-effective pathway enrichment analysis. This is the ideal choice for high-throughput screening campaigns where you need to measure the broad transcriptomic response to various therapeutic compounds.
Deploy scRNA-seq when you need to dig deeper into cellular diversity. This is essential for isolating rare stem-like cells, analyzing tumor evolution, or studying intricate immune cell interactions within a simulated co-culture microenvironment.
Bioinformatics
Deep Bioinformatics & Integrated Multi-Omics Analysis
Raw sequencing data requires sophisticated computational interpretation. Our bioinformatics team goes beyond standard automated lists, providing deep, context-rich analysis that bridges the gap between raw data and actionable biological mechanisms. We tailor our pipelines to ensure you extract the maximum value from your micro-input samples.
Minimum Deliverables
Raw FastQ data files with high Q30 quality scores
Comprehensive alignment statistics and genomic mapping rates
Basic variant calling (VCF) and Differentially Expressed Gene (DEG) lists
Detailed methodology documentation and QC parameter reports
Advanced Optional Add-Ons
Tumor-Normal Concordance Mapping: Quantitative, statistical validation of model fidelity to prove the organoid mirrors the original tissue.
Trajectory Analysis: Pseudotime mapping algorithms to track developmental lineages and cellular differentiation studies via scRNA-seq.
Integrated Pathway Profiling: Advanced cross-referencing of WES mutational data with RNA-seq expression data to identify how genetic alterations drive transcriptomic behavior.
Immune Deconvolution: Utilizing advanced algorithms to estimate immune cell abundance and composition purely from bulk transcriptomic data signatures.
Demo Results
Demo Results: Validating Model Fidelity & Heterogeneity
A primary goal of multi-omics profiling is to provide quantitative, visual proof that your 3D models retain the complex characteristics of their origin tissues. We deliver intuitive visual outputs tailored to support your preclinical decisions, ensuring your models are robust platforms for downstream assays.
Mutational Concordance (WES): We utilize targeted scatter plots demonstrating the preservation of somatic mutational allele frequencies. This proves that the genomic architecture and key driver mutations remain stable across extended culture passages.
Global Expression Heatmaps (mRNA): Hierarchical clustering matrices provide undeniable evidence of transcriptomic stability, ensuring the active signaling pathways and intrinsic molecular subtypes match the primary tissue.
Cell Population UMAPs (scRNA-seq): Dimensionality reduction plots visually demonstrate the preservation of cellular heterogeneity, clearly grouping distinct cell lineages and highlighting the presence of rare, highly impactful subpopulations.
Pathway Enrichment (Multi-Omics): Functional bubble charts map significant data to established databases (like KEGG and Gene Ontology), identifying specific up-regulated therapeutic targets and metabolic shifts.
Immune Infiltration Profiling: Deconvolution stacked bar charts map the complex immune microenvironment, estimating the preservation of specific cellular components (such as T-cells and macrophages) within simulated tumor-immune co-cultures.
Applications
Applications of Organoid Multi-Omics
By establishing a robust, multi-omics foundation, researchers can confidently deploy their 3D models across a wide spectrum of advanced translational applications. Moving beyond simple morphological observations, deep sequencing unlocks the molecular "why" behind cellular behavior.
Drug Target Discovery and Validation
Integrating WES and transcriptomic data allows teams to identify novel, highly expressed surface receptors or crucial intracellular kinases. By comparing the multi-omics profile of the disease model to normal tissue, researchers can confidently pinpoint unique vulnerabilities that are upregulated in the tumor, validating them as highly specific therapeutic intervention points.
Preclinical Biomarker Identification
The ability to link complex gene expression signatures to observed in vitro drug sensitivities is paramount. Our transcriptomic services enable researchers to identify robust, predictive biomarkers. By sequencing organoids that demonstrate resistance versus those that demonstrate sensitivity, R&D teams can isolate the specific genetic or transcriptomic drivers of that response, paving the way for future translational stratification.
Tumor Microenvironment (TME) Modeling
The tumor microenvironment is a highly complex ecosystem. Using advanced single-cell resolution or bulk immune deconvolution, researchers can quantitatively assess how well complex co-culture systems (such as tumor organoids co-cultured with fibroblasts or immune cells) maintain the specific microenvironment of the original tissue. This multi-omics profiling is vital for evaluating the efficacy of novel immunotherapies and understanding mechanisms of immune evasion.
Mechanism of Action (MoA) Profiling
Standard viability assays indicate if a compound killed a cell, but they cannot explain the underlying biological process. Comparing transcriptomic profiles of organoids before and after compound exposure reveals exactly which biological pathways are transcriptionally modulated by a therapeutic candidate. This allows for the precise mapping of on-target therapeutic effects and the early identification of potential off-target toxicities in the development pipeline.
Sample Guidelines
Sample Submission Guidelines
To ensure optimal extraction and high-quality library preparation, please strictly adhere to the following micro-input submission parameters. Safe, temperature-controlled transit is essential to prevent nucleic acid degradation before the samples reach our facility.
Sample Type
Recommended Input
Applicable Sequencing
Container / Buffer
QC Checkpoints
FNA-Derived Organoids
≥3 needles
WES & Bulk mRNA
Tissue Preservation Buffer
Fluorometric quantification & RIN
Fresh Cultured Organoids
0.6g (approx. 3 soybeans)
WES, mRNA, scRNA-seq
Tissue Preservation Buffer
Cell Viability (>80%) & RIN
Matched Primary Tissue
>0.5g (if available)
WES & Bulk mRNA
Tissue Preservation Buffer
Vital for Concordance Analysis
Case Study
Case Study: Preclinical Transcriptomic Profiling
Robust multi-omics profiling provides the definitive evidence needed to validate the biological relevance of complex 3D models. The following peer-reviewed study illustrates how single-cell transcriptomics can uncover critical disease mechanisms and stratify complex cellular states.
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a complex, multifaceted spectrum of liver pathologies, ranging from simple steatosis to severe steatohepatitis. Developing accurate, stable 3D models that successfully reflect the highly heterogeneous nature of this disease in vitro is critical for discovering novel therapeutic interventions and understanding disease progression.
The research team generated tissue-derived human liver organoid models from distinct donor backgrounds to accurately mimic the broader MASLD spectrum. To understand the intricate cellular complexity and rigorously validate the models' accuracy against known in vivo disease states, they utilized high-resolution single-cell RNA sequencing (scRNA-seq). This approach allowed them to deeply profile the transcriptomic landscape of the organoids at a single-cell resolution, moving far beyond standard bulk analysis.
As highlighted in Figure 2 of the referenced study, the comprehensive scRNA-seq data successfully stratified the organoid models based entirely on their distinct metabolic signatures. The transcriptomic profiling identified specific, distinct cellular subpopulations and highlighted critical gene expression shifts related to lipid metabolism, oxidative stress, and cellular injury pathways that closely mirror the recognized in vivo disease progression of MASLD.
The deep single-cell transcriptomic analysis provided definitive, quantitative proof that these specifically engineered organoids successfully modeled the complex cellular heterogeneity and metabolic shifts characteristic of MASLD. This robust genomic validation confirmed their utility as highly reliable preclinical platforms for future target discovery, disease modeling, and high-throughput drug screening.
Q1. How do you prevent batch effects when handling multi-omics projects?
Batch effects are a common challenge when sequencing different modalities on different days or across different laboratories. We mitigate this by utilizing an integrated, end-to-end workflow within a single facility. During the bioinformatics phase, our team applies advanced integration algorithms to computationally align datasets, removing technical noise while preserving true biological signals.
Q2. What happens if my organoid sample fails the initial extraction QC?
Transparency is a core principle of our service. If your sample yields DNA/RNA below the required concentration or fails integrity checks (e.g., low RIN or <80% viability), we will immediately pause the project. We will consult with you to discuss whether to proceed with a customized low-input rescue protocol or request a new sample, preventing wasted sequencing budgets.
Q3. Can you integrate organoid WES and scRNA-seq data into a single report?
Yes. Our advanced bioinformatics team can perform cross-omics integration. We can map the specific somatic mutations identified via WES onto the transcriptomic expression profiles generated by scRNA-seq, providing a comprehensive view of how genetic alterations drive distinct cellular behaviors.
Q4. How much starting material is required for combined WES and RNA-seq extraction?
If you intend to perform dual-omics extraction from a single batch, we recommend providing at least 0.8g of fresh organoid tissue. Our micro-input optimized kits allow us to co-extract DNA and RNA efficiently, but slightly higher biomass ensures maximum library complexity for both platforms.
Q5. Do you provide raw sequencing data (FastQ) and detailed parameter logs for publication?
Absolutely. We provide complete data transparency. Alongside the interactive bioinformatics reports, you will receive secure access to all raw FastQ files, alignment BAM files, and a comprehensive methodology log detailing the exact algorithms, versions, and parameters used, which is critical for peer-reviewed publication submissions.
Disclaimer: All services and products detailed on this page are intended for Research Use Only (RUO). They are not intended for use in diagnostic procedures, clinical decision-making, or any therapeutic applications.
For research purposes only, not intended for clinical diagnosis, treatment, or individual health assessments.
Inquiry
x
Quote Request
CD Genomics is transforming biomedical potential into precision insights through seamless sequencing and advanced bioinformatics.
